CD44 single nucleotide polymorphism and isoform switching may predict gastric cancer recurrence

Journal of Surgical Oncology

Volumn 112, Issue 6, 2015, Pages 622-628

  Suenaga, Masaya ^a   Yamada, Suguru ^a   Fuchs, Bryan C ^b   Fujii, Tsutomu ^a   Kanda, Mitsuro ^a   Tanaka, Chie ^a   Kobayashi, Daisuke ^a   Fujiwara, Michitaka ^a   Tanabe, Kenneth K ^b   Kodera, Yasuhiro ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

CD44; disease recurrence; gastric cancer; isoform switching; single nucleotide polymorphism

Indexed keywords

CD44V ANTIGEN; HERMES ANTIGEN; ISOPROTEIN; MESSENGER RNA; TUMOR MARKER;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; DISEASE FREE SURVIVAL; FEMALE; GASTRECTOMY; GASTRIC CANCER CELL LINE; GENE FREQUENCY; GENE SWITCHING; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; PERITONEAL FLUID; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; TOTAL STOMACH RESECTION; AGED; CANCER STAGING; FOLLOW UP; GENETICS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH TUMOR; SURVIVAL RATE; TUMOR CELL CULTURE; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD44; BIOMARKERS, TUMOR; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTEIN ISOFORMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 84945286810     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.24056     Document Type: Article

References (42)

1. Jemal A, Bray F, Center MM, et al.,: Global cancer statistics. CA: Cancer J Clin 2011; 61: 69-90.
2. D'Angelica M, Gonen M, Brennan MF, et al.,: Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 2004; 240: 808-816.
3. Zoller M,: CD44: Can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 2011; 11: 254-267.
4. Ozmen F, Ozmen MM, Ozdemir E, et al.,: Relationship between LYVE-1, VEGFR-3 and CD44 gene expressions and lymphatic metastasis in gastric cancer. World J Gastroenterol 2011; 17: 3220-3228.
5. Nishii T, Yashiro M, Shinto O, et al.,: Cancer stem cell-like SP cells have a high adhesion ability to the peritoneum in gastric carcinoma. Cancer Sci 2009; 100: 1397-1402.
6. Yoon C, Park do J, Schmidt B, et al.,: CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance. Clin Cancer Res 2014; 20: 3974-3988.
7. Li M, Zhang B, Zhang Z, et al.,: Stem cell-like circulating tumor cells indicate poor prognosis in gastric cancer. BioMed Res Internat 2014; 2014: 981261.
8. Jung WY, Kang Y, Lee H, et al.,: Expression of moesin and CD44 is associated with poor prognosis in gastric adenocarcinoma. Histopathology 2013; 63: 474-481.
9. Doventas A, Bilici A, Demirell F, et al.,: Prognostic significance of CD44 and c-erb-B2 protein overexpression in patients with gastric cancer. Hepato-gastroenterology 2012; 59: 2196-2201.
10. Ghaffarzadehgan K, Jafarzadeh M, Raziee HR, et al.,: Expression of cell adhesion molecule CD44 in gastric adenocarcinoma and its prognostic importance. World J Gastroenterol 2008; 14: 6376-6381.
11. Winder T, Ning Y, Yang D, et al.,: Germline polymorphisms in genes involved in the CD44 signaling pathway are associated with clinical outcome in localized gastric adenocarcinoma. Int J Cancer J Int du Cancer 2011; 129: 1096-1104.
12. Ponta H, Sherman L, Herrlich PA,: CD44: From adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003; 4: 33-45.
13. Naor D, Sionov RV, Ish-Shalom D,: CD44: Structure, function, and association with the malignant process. Adv Cancer Res 1997; 71: 241-319.
14. Brown RL, Reinke LM, Damerow MS, et al.,: CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest 2011; 121: 1064-1074.
15. Mima K, Okabe H, Ishimoto T, et al.,: CD44s regulates the TGF-beta-mediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res 2012; 72: 3414-3423.
16. Mashita N, Yamada S, Nakayama G, et al.,: Epithelial to mesenchymal transition might be induced via CD44 isoform switching in colorectal cancer. J Surg Oncol 2014; 110: 745-751.
17. Marsh S, Mallon MA, Goodfellow P, et al.,: Concordance of pharmacogenetic markers in germline and colorectal tumor DNA. Pharmacogenomics 2005; 6: 873-877.
18. van Huis-Tanja L, Kweekel D, Gelderblom H, et al.,: Concordance of genotype for polymorphisms in DNA isolated from peripheral blood and colorectal cancer tumor samples. Pharmacogenomics 2013; 14: 2005-2012.
19. Marisi G, Passardi A, Calistri D, et al.,: Discrepancies between VEGF -1154 G>A polymorphism analysis performed in peripheral blood samples and FFPE tissue. Int J Mol Sci 2014; 15: 13333-13343.
20. Zhang L, Cui G, Li Z, et al.,: Comparison of high-resolution melting analysis, TaqMan Allelic discrimination assay, and sanger sequencing for Clopidogrel efficacy genotyping in routine molecular diagnostics. J Mol Diagn 2013; 15: 600-606.
21. Park MJ, Hyun MH, Yang JP, et al.,: Effects of the interleukin-1beta-511C/T gene polymorphism on the risk of gastric cancer in the context of the relationship between race and H. pylori infection: A meta-analysis of 20,000 subjects. Mol Biol Rep 2014; 42: 119-134.
22. Yang J, Zhang G, Chen J,: CCND1 G870A polymorphism is associated with increased risk of colorectal cancer, especially for sporadic colorectal cancer and in Caucasians: A meta-analysis. Clin Res Hepatol Gastroenterol 2012; 36: 169-177.
23. Peng Q, Lao X, Chen Z, et al.,: TP53 and MDM2 gene polymorphisms, gene-gene interaction, and hepatocellular carcinoma risk: Evidence from an updated meta-analysis. PLoS ONE 2013; 8: e82773.
24. Gong WF, Zhong JH, Xiang BD, et al.,: Single nucleotide polymorphism 8q24 rs13281615 and risk of breast cancer: meta-analysis of more than 100,000 cases. PLoS ONE 2013; 8: e60108.
25. Dong S, Liu Y, Chen J,: MTHFR gene polymorphism and risk of myeloid leukemia: A meta-analysis. Tumour Biol 2014; 35: 8913-8919.
26. Suenaga M, Yamada S, Fujii T, et al.,: A functional polymorphism in the epidermal growth factor gene predicts hepatocellular carcinoma risk in Japanese hepatitis C patients. Onco Targets Ther 2013; 6: 1805-1812.
27. Easton DF, Pooley KA, Dunning AM, et al.,: Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447: 1087-1093.
28. Vazquez A, Grochola LF, Bond EE, et al.,: Chemosensitivity profiles identify polymorphisms in the p53 network genes 14-3-3tau and CD44 that affect sarcoma incidence and survival. Cancer Res 2010; 70: 172-180.
29. Zhou J, Nagarkatti PS, Zhong Y, et al.,: Unique SNP in CD44 intron 1 and its role in breast cancer development. Anticancer Res 2010; 30: 1263-1272.
30. Tulsyan S, Agarwal G, Lal P, et al.,: CD44 gene polymorphisms in breast cancer risk and prognosis: A study in North Indian population. PLoS ONE 2013; 8: e71073.
31. Chou YE, Hsieh MJ, Chiou HL, et al.,: CD44 gene polymorphisms on hepatocellular carcinoma susceptibility and clinicopathologic features. BioMed Res Int 2014; 2014: 231474.
32. Chou YE, Hsieh MJ, Hsin CH, et al.,: CD44 gene polymorphisms and environmental factors on oral cancer susceptibility in Taiwan. PLoS ONE 2014; 9: e93692.
33. Thiery JP, Acloque H, Huang RY, et al.,: Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890.
34. Biddle A, Gammon L, Fazil B, et al.,: CD44 staining of cancer stem-like cells is influenced by down-regulation of CD44 variant isoforms and up-regulation of the standard CD44 isoform in the population of cells that have undergone epithelial-to-mesenchymal transition. PLoS ONE 2013; 8: e57314.
35. Okugawa Y, Toiyama Y, Tanaka K, et al.,: Clinical significance of Zinc finger E-box Binding homeobox 1 (ZEB1) in human gastric cancer. J Surg Oncol 2012; 106: 280-285.
36. Tanabe KK, Nishi T, Saya H,: Novel variants of CD44 arising from alternative splicing: Changes in the CD44 alternative splicing pattern of MCF-7 breast carcinoma cells treated with hyaluronidase. Mol Carcinog 1993; 7: 212-220.
37. Ishimoto T, Nagano O, Yae T, et al.,: CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 2011; 19: 387-400.
38. Lau WM, Teng E, Chong HS, et al.,: CD44v 8-10 is a cancer-specific marker for gastric cancer stem cells. Cancer Res 2014; 74: 2630-2641.
39. Zeilstra J, Joosten SP, Dokter M, et al.,: Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis. Cancer Res 2008; 68: 3655-3661.
40. Hirata K, Suzuki H, Imaeda H, et al.,: CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence. Br J Cancer 2013; 109: 379-386.
41. Ni J, Cozzi PJ, Hao JL, et al.,: CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance. Prostate 2014; 74: 602-617.
42. M Sasako, M Inoue, JT Lin, et al., Gastric Cancer Working Group report Jap J Clin Oncol 40 2010; i28-i37